Skip to main content
. 2022 Nov 16;12:961194. doi: 10.3389/fonc.2022.961194

Table 4.

Univariate and multivariate analysis for predicting EHM in followed up patients.

Variable Univariate analysis Multivariate analysis
HR 95%CI p-Value HR 95%CI p-Value
Age, years 0.999 0.978-1.021 0.951
Sex
 Male
 Female 1.452 0.901–2.341 0.126
History of diabetes 0.893 0.549–1.452 0.647
History of cirrhosis 0.676 0.428–1.066 0.092
History of smoke 0.831 0.537–1.285 0.405
History of drink 0.756 0.473–1.211 0.245
BMI 0.978 0.915–1.046 0.517
Child–Pugh
 A 0.256 0.034–1.913 0.184
 B 0.300 0.039–2.289 0.245
 C
WBC, ×109/L 1.063 0.970–1.164 0.192
NE, % 1.028 1.009–1.048 0.004 1.021 1.000–1.044 0.044
HB, g/L 1.000 0.994–1.006 0.930
PLT, ×109 1.002 0.999–1.005 0.187
ALT, U/L 1.000 1.000–1.001 0.245
AST, U/L 1.001 1.000–1.001 0.093
TP, g/L 0.975 0.950–1.001 0.057 0.970 0.942–0.998 0.039
ALB, g/L 0.975 0.932–1.020 0.267
GLO, g/L 0.975 0.944–1.007 0.123
TBIL, μmol/L 1.002 0.997–1.007 0.376
DBIL, μmol/L 1.003 0.997–1.009 0.331
ALP, U/L 1.001 1.000–1.003 0.117
CHE, U/L 1.000 1.000–1.000 0.765
INR 1.009 0.970–1.049 0.663
TT, s 0.997 0.936–1.063 0.932
DD, mg/L 1.012 0.993–1.031 0.224
APTT, s 1.014 0.984–1.044 0.368
FIB, g/L 1.102 0.952–1.277 0.194
PT, s 1.015 0.922–1.117 0.765
AFP, ng/ml 1.000 1.000–1.000 0.309
CA19-9 ≥35 U/ml 1.000 0.999–1.001 0.917
CEA ≥5 ng/ml 6.240 2.832–13.747 0.000 1.281 1.100–1.491 0.001
HBsAg, positive 1.290 0.796–2.091 0.302
Anti-HCV, positive 0.273 0.037–2.016 0.203
Tumor number 1.049 0.892–1.235 0.562
Tumor sizes, cm 1.083 1.032–1.136 0.001 1.072 1.014–1.134 0.014
Vascular invasion 1.705 1.051–2.764 0.031
Tumor location
 Left lobe 1.294 0.547–3.059 0.558
 Right lobe 0.939 0.606–1.454 0.778
 Bilateral lobe

BMI, Body Mass Index; WBC, White Blood Cell Count; NE, Neutrophil; HB, Hemoglobin; PLT, Platelet Count; ALT, Alanine Amiotransferase; AST, Aspartate Aminotransferase; TP, Total Protein; ALB, Albumin; GLO, Globulin; TBIL, Total Bilirubin; DBIL, Direct Bilirubin; ALP, Alkaline Phosphatase; Cr, Creatinine; CHE, Cholinesterase; INR, International Normalized Ratio; TT, Thrombin Time; DD, D-Dimer; APTT, Activated Partial Thromboplastin Time; FIB, Fibrinogen; PT, Prothrombin Time; AFP, α-Fetoprotein; CEA, Carcinoembryonic Antigen; CA19-9, Carbohydrate Antigen 19-9;HBsAg, Hepatitis B Surface Antigen; Anti-HCV, Anti-Hepatitis C Virus Antibody.